Skip to content

About Us
Product Pipeline
Marketed Products

News

Contact Us

Stay up to date with our latest research
and corporate developments

Latest News & Media

News

2019/8/30

TaiRx ranked first in Taiwan for the most innovative pharmaceutical companies in the APAC region

World-renowned professional information services company, Clarivate Analytics, released a special re…
[Read More]
2019/1/2

TaiRx receives “Technology and Product or Technology Development is Successful and Marketable” recommendation from Industrial Development Bureau and starts CVM-1118 (Foslinanib) Phase II clinical trial in Taiwan and US.

TaiRx, Inc. (6580) announces good news at the start of 2019 that it receives “Technology and Product
[Read More]
2018/10/23

TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics- Joint venture to focus on the Nodal protein, a previously untargeted and critical mediator of aggressive cancer progression and treatment resistance

TaiRx, Inc and BioHealth Innovation, Inc. (BHI) announced today the formation of TaiRx US, a new joi…
[Read More]
2018/4/15

A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.

TaiRx’s CVM-1118 small molecule cancer drug received US FDA approval on April 15th to conduct multi-…
[Read More]

←Previous Page

1 2 3 4 5 … 7

Facebook
Link
YouTube
Instagram

Copyright© 2026 TaiRx, inc.